Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check16 days agoChange DetectedThe web page has updated a date from March 8, 2024, to April 17, 2025.SummaryDifference0.9%
- Check23 days agoChange DetectedThe web page has updated its version from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.